Our findings in mice, cells, and patient-derived organoids suggest that HCC patients with high tumoral arginine levels (i.e., loss of ARG1 and AGMAT and gain of ASNS) and elevated RBM39 levels would benefit from treatment with aryl sulfonamides. Here, AGMAT is linked to hepatocellular carcinoma.